Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03137160 · ClinicalTrials.gov registry record · Phase 2
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
A Phase 2 study, sponsored by Ohio State University.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03137160 is a Phase 2 study that has completed, run by Ohio State University. The registered enrollment target is 4 participants.
The verdict
NCT03137160, a Phase 2 study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
Interventions
- BIOLOGICAL Ixekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-05-04 |
| Est. Completion | 2018-08-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03137160
The ClinicalTrials.gov registry entry for NCT03137160 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ixekizumab is the first listed.
NCT03137160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03137160 about?
NCT03137160 is a clinical study titled "An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum". An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
What is the current status of trial NCT03137160?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2017-05-04. Estimated completion is 2018-08-16.
What interventions are being tested in trial NCT03137160?
The interventions under investigation include: Ixekizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03137160?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.